Frontiers in Pharmacology (Feb 2019)

G Protein-Coupled Receptor Kinase 2 (GRK2) as a Potential Therapeutic Target in Cardiovascular and Metabolic Diseases

  • Cristina Murga,
  • Cristina Murga,
  • Cristina Murga,
  • Alba C. Arcones,
  • Alba C. Arcones,
  • Alba C. Arcones,
  • Marta Cruces-Sande,
  • Marta Cruces-Sande,
  • Marta Cruces-Sande,
  • Ana M. Briones,
  • Ana M. Briones,
  • Ana M. Briones,
  • Mercedes Salaices,
  • Mercedes Salaices,
  • Mercedes Salaices,
  • Federico Mayor Jr.,
  • Federico Mayor Jr.,
  • Federico Mayor Jr.

DOI
https://doi.org/10.3389/fphar.2019.00112
Journal volume & issue
Vol. 10

Abstract

Read online

G protein-coupled receptor kinase 2 (GRK2) is a central signaling node involved in the modulation of many G protein-coupled receptors (GPCRs) and also displaying regulatory functions in other cell signaling routes. GRK2 levels and activity have been reported to be enhanced in patients or in preclinical models of several relevant pathological situations, such as heart failure, cardiac hypertrophy, hypertension, obesity and insulin resistance conditions, or non-alcoholic fatty liver disease (NAFLD), and to contribute to disease progression by a variety of mechanisms related to its multifunctional roles. Therefore, targeting GRK2 by different strategies emerges as a potentially relevant approach to treat cardiovascular disease, obesity, type 2 diabetes, or NAFLD, pathological conditions which are frequently interconnected and present as co-morbidities.

Keywords